PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDalfampridine
Ampyra, Fampyra(dalfampridine)
Ampyra, Dalfampridine (dalfampridine) is a small molecule pharmaceutical. Dalfampridine was first approved as Ampyra on 2010-01-22. It is used to treat multiple sclerosis and neurologic gait disorders in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ampyra, Dalfampridine (discontinued: Dalfampridine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dalfampridine
Tradename
Company
Number
Date
Products
AMPYRAMerzN-022250 RX2010-01-22
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ampyraNew Drug Application2025-05-05
dalfampridineANDA2025-07-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple sclerosisEFO_0003885D009103G35
neurologic gait disorders—D020233R26.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07X: Other nervous system drugs in atc
— N07XX: Other nervous system drugs in atc
— N07XX07: Fampridine
HCPCS
No data
Clinical
Clinical Trials
266 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35—111591142
SclerosisD012598———11158838
PyelonephritisD011704EFO_1001141N10-N16—251—7
Whooping coughD014917EFO_0000650A372—2116
DiphtheriaD004165EFO_0005549A361—21—4
MalariaD008288EFO_0001068B541——2—3
IschemiaD007511EFO_0000556——2—1—3
TetanusD013742EFO_0005593A351—11—3
PoliomyelitisD011051EFO_0007450A80——21—3
Falciparum malariaD016778EFO_0007444B501——1—2
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SyndromeD013577——333—1119
Lambert-eaton myasthenic syndromeD015624EFO_0020094G70.80—13—913
Non-small-cell lung carcinomaD002289——452—212
Lung neoplasmsD008175—C34.90361—211
NeoplasmsD009369—C80541—19
Wounds and injuriesD014947—T14.8164——9
Urinary tract infectionsD014552EFO_0003103N39.0—26—18
InfectionsD007239EFO_0000544——23—26
Spinal cord injuriesD013119EFO_1001919—223——6
Congenital myasthenic syndromesD020294Orphanet_590G70.2——1—56
Show 43 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C951110———14
Healthy volunteers/patients———82——210
Myeloid leukemiaD007951—C9267———9
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—56———8
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.054——17
LymphomaD008223—C85.935———6
Non-hodgkin lymphomaD008228—C85.924———5
RecurrenceD012008——32———5
CarcinomaD002277—C80.022———4
AdenocarcinomaD000230——12——14
Show 104 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E101———910
Diabetes mellitusD003920EFO_0000400E08-E131———67
PeriodontitisD010518EFO_0000649K05.31———23
Periapical periodontitisD010485EFO_1001391K04.51———23
GlioblastomaD005909EFO_0000515—2————2
Cerebral palsyD002547—G801———12
Huntington diseaseD006816Orphanet_399G102————2
Anxiety disordersD001008EFO_0006788F41.11———12
Hepatocellular carcinomaD006528—C22.01————1
Motor neuron diseaseD016472EFO_0003782G12.21————1
Show 12 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382—U07.1————33
OsteoarthritisD010003EFO_0002506M15-M19————33
Sleep initiation and maintenance disordersD007319—F51.01————22
AsthmaD001249EFO_0000270J45————22
Peripheral nervous system diseasesD010523—G64————22
HypoglycemiaD007003—E16.2————22
Bone fracturesD050723EFO_0003931T14.8————22
DermatitisD003872—L30.9————22
Patellofemoral pain syndromeD046788EFO_1001092—————22
Post-traumatic stress disordersD013313EFO_0001358F43.1————22
Show 113 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDalfampridine
INNfampridine
Description
4-aminopyridine is an aromatic amine that is pyridine bearing a single amino substituent at position 4. An orphan drug in the US, it is used to improve walking in adults with multiple sclerosis. It has a role as an avicide, a potassium channel blocker and an orphan drug. It is an aromatic amine and an aminopyridine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1ccncc1
Identifiers
PDB—
CAS-ID504-24-5
RxCUI—
ChEMBL IDCHEMBL284348
ChEBI ID34385
PubChem CID1727
DrugBankDB06637
UNII IDBH3B64OKL9 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Ampyra – Acorda Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Ampyra – Alkermes
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Ampyra – Elan Corporation
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Ampyra – Biogen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Fampyra – Biogen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dalfampridine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,132 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
66,308 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use